Advanced Cell Technology pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE.
In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).
In 2014, Advanced Cell Technology changed its company name to Ocata Therapeutics. In 2016 Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc. and Ocata Therapeutics became a subsidiary of Astellas. In 2018 the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).
Advanced Cell Technology Changes Name to Ocata Therapeutics
Documentaries, videos and podcasts
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: Stem cell technologyTechnology used for isolating, generating, growing and controlling the differentiation of stem cells into specialized cells and the application of stem cell technology for medical and non-medical purposes such as producing meat through cellular agriculture.
- Stem cellStem cells are self-renewing cells that have the potential to become multiple different cell types in the body. Stem cells are found in developing embryos. Adult stem cells maintain and repair tissues throughout life. Induced pluripotent stem cells are a type of stem cell derived from adult cells that are reprogrammed in the lab.
- Regenerative medicineBranch of research dealing with the process of replacing, engineering, or regenerating biological units to (re-)establish normal function